| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192745 | Journal of Thoracic Oncology | 2016 | 25 Pages |
Abstract
In the Netherlands between 2010 and 2013, 15% of patients with cIIIA NSCLC received an operation, with the minority of these patients receiving induction therapy. In those receiving induction therapy, 90-day mortality after bilobectomy or pneumonectomy was more than three times higher than that for lobectomy. The discrepancy between clinical and pathological stage in patients receiving an upfront operation merits further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Chris MD, Max MBChB., PhD, A. Joop MD, PhD, Marinus A. MD, PhD, Egbert F. MD, PhD, Suresh MD, PhD, Koen J. MD, PhD, Ronald A. MD, PhD,